1236670-89-5

Upstream product

• 1236670-87-3 2-chloro-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-4-pyrimidineamine 
• 80213-28-1 3-methylsulfonylaniline hydrochloride 
• 76-05-1 trifluoroacetic acid 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 14733-77-8 5-amino-2-benzoxazolinone 

Relevant academic research and scientific papers

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.